A Cross-Sectional Study of Symptom Prevalence, Frequency, Severity, and Impact of Long-COVID in Scotland: Part I

Marie Mclaughlin¹, Luke Cerexhe¹, Eilidh Macdonald¹, Joanne Ingram², Nilihan E.M. Sanal-Hayes¹, Lawrence D. Hayes¹, Rachel Meach¹, David Carless¹, Nicholas Sculthorpe¹

¹ Sport and Physical Activity Research Institute, School of Health and Life Sciences, University of the West of Scotland, Glasgow, United Kingdom

²School of Education and Social Sciences, University of the West of Scotland, Paisley, United Kingdom

Abstract

Background: Commonly reported symptoms of long-COVID may have different patterns of prevalence and presentation across different countries. While some limited data has been reported for the UK, national specificity for Scotland is less clear. We present a cross-sectional survey to examine the symptom prevalence, frequency and severity of long-COVID for people living with the condition in Scotland.

Methods: An online survey was created in the English language and was available between 21st April 2022 and 5th August 2022. Participants were included if they were ≥18 years old, living in Scotland, and had self-diagnosed or confirmed Long-COVID; and excluded if they were hospitalised during their initial infection. Within this article we quantify symptom prevalence, frequency, severity, and duration.

Results: Participants (n=253) reported the most prevalent long-COVID symptoms to be postexertional malaise (95%), fatigue/tiredness (85%), and cognitive impairment (68%). Fatigue/tiredness, problems with activities of daily living (ADL), and general pain were most frequently occurring, whilst sleep difficulties, problems with ADL, and nausea were the most severe. Scottish Index of Multiple Deprivation associated with symptom number, severity and frequency, while vaccine status, age, sex, and smoking status had limited or no association.

Conclusions: These findings outline the challenges faced for those living with long COVID and highlight the need for longitudinal research to ascertain a better understanding of the condition and its longer-term societal impact.

Key Words: Long-COVID, PASC, PAIS, survey, symptoms

Introduction

Long-COVID has been defined as symptoms which develop or continue weeks or months after acute SARS-CoV-2 infection, and which persist for more than 12 weeks without an alternative explanation ¹. It is part of a group of conditions known as post-acute infection syndromes (PAISs), characterised by a failure to recover from an infectious agent, including bacteria, viruses, and parasites. As a result, these conditions often cause commonly overlapping symptoms such as poor functional status, exertion intolerance, debilitating fatigue, and sleep quality disturbances ². With the sheer scale of the COVID-19 pandemic since its first detection in December 2019, long-COVID has been recognised as a significant impact for the global population not previously noticed in other PAISs ².

The most commonly reported symptoms of long-COVID are fatigue, shortness of breath, and cognitive impairment, or 'brain fog' ³. However, there are more than 100 different symptoms which have so far been reported in the literature, with heterogeneity in reported symptom prevalence within different geographical locations ³. For example, at 60-days post-infection, fatigue and dyspnoea have been reported to have a prevalence of 87% and 71%, respectively, across the Netherlands and Belgium ⁴; 55% and 45% in New Jersey ⁵; and 53% and 43% in Italy ⁶. While research has been conducted to establish symptom prevalence across the whole of the United Kingdom (UK) ⁷, there remains limited understanding of the nature, and consequences of long-COVID for specific geographical regions and countries, including Scotland. Scotland has some of the worst health inequalities in western and central Europe⁸, and has the highest incidence of alcohol- and drug-related deaths⁹, prevalence of cardiovascular disease, stroke, cancer¹⁰, and multiple sclerosis¹¹, compared with other UK nations. Higher prevalence of health problems within the nation of Scotland may influence symptom data and therefore, it is important to characterise long COVID specific to this nation.

At the time of writing, the Office for National Statistics (ONS) in the UK has estimated around 1.9 million people in the UK are living with long-COVID, of which 172 thousand reside in Scotland ¹². The result of this is over 3% of the estimated Scottish population ¹³ living with additional health needs. Within this paper we map out the prevalence, frequency, and severity of long-COVID symptoms experienced by those living in this UK nation.

Methods

Study Design

This cross-sectional observational study was funded through the Chief Scientist Office funding call for Scottish-led research on long-term effects of COVID-19 infection (COV/LTE/20/08). All respondents gave digital informed consent before participating in an online survey consisting of questions regarding their experience of long-COVID. Survey responses contained no personally identifiable information. Ethical approval was granted by the School of Health and Life Sciences Ethics Committee at the University of the West of Scotland ethical review committee (ethics number 14019).

An online survey was created in the English language and embedded to our project specific website: <u>UWS Long Covid (uws-projects.co.uk)</u>. Survey questions were curated based on symptoms our previously reported scoping review of the literature ³ and the impact of these symptoms. Included were questions regarding participant demographics, symptom prevalence, frequency, severity, and duration, and impact of long COVID on work, study, and caring duties, as well as ratings of current emotional well-being. To ensure understanding, questions containing medical jargon where accompanied with a description in plain language.

The survey was launched on 21st April 2022 and advertised directly to relevant patient support groups and on social media platforms, Twitter, and Facebook. Data used in this study were collected from 21st April until 5th August 2022.

Participant Demographics and Study Population

Respondents reported their age, sex, ethnicity, vaccination status, underlying health conditions, smoking status, type of home, marriage status, household income, and post-code. Scottish Index of Multiple Deprivation (SIMD) was determined by post-code using the website: <u>SIMD (Scottish Index of Multiple Deprivation)</u>. From this, 5 categories were created with quintile 1 representing the most deprived areas (low SIMD) to quintile 5 representing the least deprived areas (high SIMD).

Participants were included if they were ≥18 years old, living in Scotland (determined by their postcode), and had either self-diagnosed or confirmed Long-COVID, regardless of presence of SARS-Cov-2 testing at the time of initial suspected infection. Individuals were excluded from participation if they were hospitalised during their initial infection. Analysis was limited to respondents with illness lasting at least 4 weeks and symptom onset from December 2019 onwards.

Study Outcomes

This study quantified symptom prevalence, frequency, severity, duration and ratings of current emotional wellbeing. Data on the impact of long-COVID on work, study, and caring duties was also collected and is reported in Part 2 (<u>CITATION TO PART 2 MANUSCRIPT – EDITORIAL MANAGEMENT</u>).

Symptom Number and Prevalence

Thirty-six symptoms ³ were investigated by identifying their presence or absence at the current time of survey completion. For each respondent, a total number of symptoms reported was calculating a mean ± SD to the nearest whole number. Additionally, prevalence was calculated for each symptom by dividing the number of those who reported experiencing the symptom by the total number of survey respondents.

Symptom Frequency, and Severity

Respondents rated the frequency (more than once per day, every day, every week, more than once per week) and severity (mild, moderate, severe, very severe) for each of the symptoms experienced. Frequency and severity responses were reported as percentages of the total number of those experiencing the symptom of interest.

Duration and Improvement Rating of Long-COVID

The duration of long COVID was calculated based on the reported date of starting to experience long COVID to the date the survey was completed. Participants were asked to grade whether they are still experiencing worst symptoms of long COVID at the time of survey completion or whether they have had some level of recovery. For those who answered that they have now seen a recovery, they were asked to grade the level of recovery on a 10-point Likert scale.

Statistical Analysis

Data was analysed using Jamovi version 2.3.12 and GraphPad Prism version 9. Shapiro-Wilks tests were performed to determine normality of data distribution. All data was determined to be normally distributed. T-Tests and analyses of variance (ANOVAs) were performed to determine between-group differences for sex and smoking status. Correlation coefficients were determined using Spearman's Rho, Mann Whitney U, and Krustal Wallis tests to determine associations of Long-COVID symptoms with demographics, including vaccination status, SIMD, age. All statistical tests where $p \le .05$ have been reported, tests where p > .05 have been reported where this information is pertinent. Data are presented as mean \pm standard deviation (SD).

Results

Between April 2022-August 2022A total of 253 respondents with a median illness duration of 25.6 \pm 15.6-months completed the survey. 55.9% of respondents answered "Yes" to being tested at the time of infection. 77.2% of respondents were female, 21.1% male, 0.4% non-binary and 1.3% prefer not to say.

Table 1. Participant Demographics

	Combined	Males	Females
Ethnicity (%)			
White British	90.4	95	90.8
White Irish	2.2		2.4
Any other white background	5.2	5	3.6
Chinese	0.4		1.3
Asian/British Asian - Indian	0.4		1.3
Asian/British Asian – Pakistani	0.4		0.6
Mixed – white and black	0.4		
African	0.4		
Other	0.4		
Age (years; Mean ± SD; range)	47.4 ± 11.3 (22-72)	47.9 ± 8.9 (35-70)	46.2 ± 11.4 (22-72)
BMI (Kg/m ² ; Mean ± SD)	29.7 ± 17.4	27.7 ± 4.5	29.9 ± 10.4
Smoking Status (%)			
Non-smoker	78.3	65	85.3
Smoker	1.8	5	1.3
Former Smoker	19.9	30	13.3
Average household income (£; Mean ± SD)	46919 ±	44310 ±	45091 ±
	27303	25434	26555
Previous diagnosis of physical or mental health	27.4	21.7	29
condition (%)			
Living with number of adults (%)			
0 adults	3.2	2.2	4.2
1 adult	21.7	19.57	20.66
2 adults	60.5	69.57	57.75
3 adults	8.3	4.35	7.51
4 adults	5.5	4.35	7.51
5 adults	0.8	0	0.47
Type of Home (%)			
Semi-detached	62.1	52.17	62.44
Detached	16.5	15.22	14.08
Flat	16.5	21.74	13.15
Terraced house	4.5	8.70	3.76
Marriage status (%) Living together but not married or in a civil partnership	13.8	6.5	15
Married	93.1	95.6	91.1

Single (never married or never registered a same- sex civil partnership)	19.0	15.2	21.1
Widowed or surviving partner from same-sex civil partnership	1.2	2.2	0
Divorced or formally in a same-sex civil partnership which is now legally dissolved	5.5	0	6.1
In a registered same-sex civil partnership	0.4	2.1	0
Separated but still legally married or still legally in a same-sex civil partnership	1.6	6.5	1.9
Underlying health conditions (%)			
Yes	27.4	21.7	29.1
Asthma	17.4	15.22	14.08
Breathing problems or other lung conditions	4.2	2.17	2.82
Diabetes	4.7	4.35	3.29
Heart Disease	4.8	6.5	2.82
Hepatitis	0.5	0	0.47
Hypertension,	10.8	8.7	7.51
Other	14.7	23.9	16.43
Vaccination Status (%)			
Yes - 2 doses plus booster	50.2	63.04	38.50
Yes - 3 doses	22.5	6.52	24.41
Yes - 3 doses plus booster	4.3	0	5.63
Yes - Can't remember date of vaccination(s)	10	15.2	8.45
Yes - 2 doses	6.5	9.57	4.72
No	4.8	2.17	3.76
Yes - 1 dose	1.7	2.17	0.94

Number of Symptoms

Mean combined number of symptoms reported was 13 ± 7 . The number of symptoms reported was not different between males 12.65 ± 6.66 and females 13.04 ± 6.52 (p = 0.71). ANOVA showed that respondents from the highest SIMD areas (lowest quintile) were more likely to report a higher number of symptoms (Average reported symptom number: 15.81 ± 4.97 , 13.73 ± 7.10 , 10.9 ± 6.61 , 10.93 ± 4.92 , 11.82 ± 6.77 for SIMD 1, 2, 3, 4, 5, respectively, *p*=0.031 for SIMD group 1 vs SIMD group 4, all other pairwise comparisons were non-significant p > 0.05). ANOVAs also revealed a greater number of symptoms were reported by smokers vs non-smokers ($20.25 \pm 6.85 \text{ vs} 11.75 \pm 6.43$; p= 0.028) and smokers vs those who used to smoke ($20.25 \pm 6.85 \text{ vs} 11.97 \pm 6.69$; p = 0.044). Independent t-tests showed a greater number of symptoms reported in those with existing conditions vs those without existing conditions ($14.9 \pm 6.27 \text{ vs} 12.08 \pm 6.43$; p = 0.002). Pearson's correlation revealed that the duration of long-COVID was associated with fewer number of symptoms reported (r = -0.1865, p = 0.003). Pearson's correlation analyses showed age did not correlate with number of symptoms reported (p = 0.26). ANOVA revealed no difference between vaccination status and symptom number (p = 0.64).

Symptom Prevalence

The most prevalent symptoms were PEM (95.26%, n = 239), fatigue/tiredness (84.58%, n = 212), and cognitive impairment (68.38%; n = 172 **Figure 1**). PEM was defined as being disproportionately tired after small amounts of activity. For those reporting PEM, 8.9 ± 18.5 hours was the average reported recovery duration after being active, with 16.7% (n = 40) meeting the MECFS PEM criteria of \geq 14 hours recovery duration ¹⁴. Chi squared analysis revealed PEM prevalence was similar in females vs males (94.57% vs 95.32%, p = 0.723). The prevalence of general fatigue/tiredness (i.e., unrelated to any preceding activity) was higher in females vs males (94.58% vs 85.42%, p = 0.013). Similarly, the prevalence of cognitive impairment was higher in females than males, but this did not reach significance (77.34% vs 68.75%, p = 0.211).

Symptom Frequency and Severity

The most frequently occurring symptoms were fatigue/tiredness, problems with activities of daily living, general pain, mobility problems, and PEM; with 65.8%, 55.9%, 50%, 49.3%, and 48.1%, reporting these symptoms as being constantly present, respectively (**Figure 2A**). Notably, Spearman's rho revealed that the duration of long-COVID was associated with more frequent muscle and joint pain (p = 0.008). Vaccination status was negatively associated with the frequency of runny nose (r = -0.44, p = 0.009), sore throat (r = -0.2191, p = 0.032), dizziness/vertigo (r = -0.234, p = 0.04), and eye irritation (r = -0.3406, p = 0.006). Higher deprivation (lower SIMD quintile) was associated with more frequent cough (Spearman's rho = -0.23, p = 0.0289), general pain/discomfort (Spearman's rho = -0.28, p = 0.0001), and muscle weakness (Spearman's rho = -0.05, p = 0.009).

The most severe symptoms reported were sleep difficulties, problems with activities of daily living, nausea, and PEM, with 37.3%, 33.3%, 31.6%, and 31.0% reporting the symptom as highly debilitating, respectively (**Figure 2B**). Greater duration of long-COVID was associated with more severe muscle and joint pain (p = 0.011), chest pain (p = 0.0002), and mobility impairment (p = 0.002). Furthermore, more severe chest pain was reported in those with more vaccinations (r = 0.52, p = 0.0009),this was the only association between vaccination status and the severity of symptoms reported. Higher deprivation (lower SIMD quintile) was associated with more severe breathlessness (Spearman's rho = -0.23, p = 0.012) and dizziness (Spearman's rho = -0.24, p = 0.04).

Regarding the changeable nature of the severity of long COVID, 53.8% of respondents reported that they were still experiencing the worst long-COVID at the time of survey completion, with 24.4% reporting long-COVID was at its worst \geq 6 months ago and 22.8% reporting long COVID was at its worst <6 months ago. Of those surveyed, 94.2% suffer from symptom relapses.



Figure 1. Percentage prevalence of symptoms in 253 respondents.



Figure 2. Symptom frequency (A) and severity (B) as a percentage of those reporting the symptom. *ADL* = *Activities of daily living.* **Missing responses for frequency data.*

Discussion

This study investigated the frequency, severity, and impact of symptoms experienced by those with long COVID residing in Scotland. The individuals in responding to this survey were not hospitalised with initial COVID-19 acute infection. It is important to characterise symptoms in these individuals as the lack of formal records (e.g. hospital records) means they are often omitted from studies ^{6,15} despite accounting for the majority of sufferers (>50 000 hospitalisations vs 2.1 million reported positive cases in Scotland ¹⁶).

For people in Scotland, long-COVID remains a multi-factorial condition with a wide range of symptoms and, in line with other studies, the most prevalent is fatigue. However, people with long-COVID in our study also report a significant amount of chronic pain, which is most severe in those who have had the condition the longest.

Prevalence

Fatigue was reported by 84.6% of participants within this study, which is greater than the pooled data from systematic reviews investigating symptoms of long-COVID found to be 32% (95% CI, 27–37)¹⁷, 58% (95% CI, 42–73)¹⁸, and 31% (95% CI 23.91–39.03)¹⁹. Muscle weakness was reported by 51% of participants in the current study. This is supported by a recent review²⁰, which reported weakness to be prevalent in 41% (95% CI 25.43–59.01) of participants within the pooled literature. PEM was reported in 95.3% of participants. While PEM has not yet been sufficiently reported to include within review literature ²¹, our study's findings closely match the findings of a Canadian observational study investigating chronic fatigue and post-exertional malaise in participants (n=211) living with long-COVID ²². Twomey et al²² found that 94.8% of participants scored above the threshold of 1 of the first 5 items of the 10-item DePaul Symptom Questionnaire–Post-Exertional Malaise (DSQ-PEM), however, only 58.7% met the full threshold used to qualify individuals for ME/CFS. This indicates the greater depth of research required to determine the true extent of PEM in people living with long-COVID, and what proportion experience PEM to a similar extent of those living with ME/CFS. The current study adds new insights that for the 95.3% of respondents reporting PEM, only 16.7% met the MECFS PEM criteria of \geq 14 hours recovery duration ¹⁴.

Chronic pain was a commonly reported symptom including joint pain (16.9%) and muscle pain (21.3%).This confirms the broader findings of a systematic review investigating prevalence of long-COVID-19 symptoms ²³, reporting prevalence of 25% (95% Cl 13–37) for muscle pain and 20% (95% Cl 13–27) for joint pain. General pain, reported in 41.1% of participants within the current study, is also comparable with that of the findings of a systematic review investigating qualify of life in post-acute COVID-19 syndrome ²⁴. Malik et al. found pain and discomfort to be reported in 41.5% (95% Cl 28–55) of cohorts in the published literature. Findings of our investigation differed considerably from that of wider research was that for headache symptoms (58.5%); far more prevalent than values reported in systematic reviews of by both Aiyegbusi et al. (18% (95% Cl 9–27))²³ and Malik et al. (21% (95% Cl 3–47))²⁴. It is unclear as to why this may be so concentrated amongst the current cohort and as such, further research is required to understand the pathology of COVID-19.

Breathlessness was reported by 64.8% of participants, which is greater than the findings of the broader review literature, who reported shortness of breath to affect 32% (95% CI 18–47;, 39.5% (95% CI 20-60)²⁴, and 43% ²⁵ of pooled data from previous reviews. Palpitations were reported by 53.8% of participants within the current study, which is similar to the pooled prevalence of 58% reported in a review of the link between long-COVID and cardiovascular autonomic dysfunction ²⁵, though far beyond the range reported in another review article ²⁶ of <6% of the pooled data. Chest

pain was reported by 49% of participants, which is greater than the pooled prevalence of 30% 25 , 15% (95% CI 9–20) 23 and 10% (95% CI 5–16) 24 reported within the review literature.

Cognitive impairment was reported by 68.38%. Although not specifically reported within the review literature available to the authors, another study (n = 2526) with the majority of participants residing in the UK (79.9%)²⁸ reported cognitive dysfunction in 69.2% of participants with long-COVID; comparable with the findings of this study. Sleep difficulties were reported by 57.7% of participants, which is comparable though slightly higher than the findings of one review ²⁷ who reported sleep disturbances in 47% (95% CI 7–89) of pooled participants.

Duration of Long-COVID

There was an inverse relationship between the duration of long-COVID and the number of symptoms reported. This suggests that the early phase of long-COVID might include a greater number of symptoms, which may underpin the breadth of symptoms previously reported ³. However, as the condition proceeds, the reported symptoms appear to concentrate on a smaller number, with fatigue and pain being among the most prevalent. Importantly, however, is that the increased duration of long-COVID is also associated with increased severity of fatigue, general pain, and muscle and joint pain. Therefore, it appears that in those people who have experienced long- COVID the longest, tend to have a smaller number of more severe symptoms.

Frequency & Severity

One aim of this study was to ascertain some measure of symptom load. We asked respondents to report not only what symptoms they experienced but also how often (i.e., days per week) and how severe they felt the symptoms were, as it is clear that symptom load varies, both within and between people with long-COVID³. We chose to separate out severity and frequency as symptom equivalence is difficult to quantify. For example, it is not clear if we should consider a modest headache that occurs daily as an equivalent symptom to a headache that only occurs rarely but is debilitatingly severe. As such, attempts to simplify frequency and severity data with a global score would be arbitrary and obscure important information, and so we reported frequency and severity data separately.

The most frequently occurring symptoms were reported to be fatigue/tiredness, problems with activities of daily living, general pain, mobility problems, and PEM, with 65.8%, 55.9%, 50%, 49.3%, and 48.1%, respectively, reporting these symptoms as being constantly present. Comparison with previous work is difficult since most studies have reported the prevalence but not the frequency of the symptoms, so additional questions determining how often these symptoms are experienced help to highlight the impact that these symptoms are having on people's lives. One UK study used similar time periods on which to ask about symptom frequency²⁸, however, these results encompass overall long-COVID symptoms and do not detail specific symptoms which may occur more frequently than others.

The most severe symptoms reported are sleep difficulties, problems with activities of daily living, nausea, and PEM, with between 30-40% of participants reporting the symptom as highly debilitating. This differs somewhat with the findings of another UK-based questionnaire study (n=812), which found the most common symptoms reported as severe to be fatigue (55.3%), brain fog (30.7%), myalgia (24.1%), shortness of breath (21.9%) and insomnia (21.1%)²⁹. The study scored severity using a visual analogue scale (mild score =1–4, moderate score = 5–7 and severe score 8–10). It is unclear as to why the results would be different between this study and the current study, however, individual symptom severity is rarely reported within the long-COVID literature and to the authors'

knowledge is the first to do so for data obtained in Scotland. This information should provide some guidance for future research and healthcare settings to deploy and develop counteractive interventions against the most debilitating symptoms identified.

The nature of long-COVID is that the symptoms fluctuate in nature and severity ^{28,30}. In the current study, 94% of respondents reported suffering from symptom relapses. This is similar to another study at 7-months post-COVID, with 85.9% of participants experiencing relapses, primarily triggered by exercise, physical or mental activity, and stress ³⁰. The current study did not explore the potential causes for relapse in symptoms and this should be explored in future studies.

Respondents reported high levels of negative emotions, including anger, sadness, and anxiety. This highlights the detrimental impact on the wellbeing and quality of life of those suffering from long-COVID and provides advocacy for these individuals. This is important to emphasise the case for long-COVID to have larger funding for research and to improve and develop healthcare initiatives throughout Scotland to help treat people suffering from the condition.

Vaccine status

While vaccine status was found to have a minor negative association with the frequency of runny nose, sore throat, dizziness and vertigo, and eye irritation, it broadly wasn't associated with number, severity or frequency of symptoms, respondents' mood (see Part 2), or impact on their work or study. This is supported by the findings of another study which found vaccine administration to have no effect on long-COVID symptom improvement ³¹. However, another study investigating the effects of vaccine administration on long-COVID symptoms ²⁹ found an improvement in most self-reported symptoms after participants had received a vaccine dose. Without knowing how severe this study's participants' long-COVID symptoms would have been in the absence of their vaccine, firm conclusions cannot be drawn and clarity on the aetiology of long-COVID and the effects of vaccination on symptoms in needed.

Age

No significant correlations were found in relation to age. This contradicts the findings of an appbased observation study of 4128 participants found a significant positive correlation between age and duration of long-COVID in participants >70 years ³². However, few participants within our study were over the age of 65 years. This may have been due to the use of an online survey as a barrier however, similar barriers would have faced participants from Sudre et al., (2021)³².

<u>Sex</u>

There were a greater number of female participants in this study (77% female to 21% male, 0.4% non-binary, 1.3% prefer not to say), reflecting, albeit to a greater degree than some of the literature, the increased prevalence of long-COVID among women over a population ³³. Sex differences were in proportional impact, however, were only found in differences for fatigue and tiredness (94.58% vs. 85.42%), and cognitive impairment (77.34% vs. 68.75%); both were more prevalent in women. While these findings have been supported by a review of sex differences in long-COVID symptoms ³³.

SIMD

We found that respondents from more deprived areas (lower SIMD quintile) were significantly more likely to report a higher number of symptoms than those from higher SIMDs. Furthermore, lower SIMD was associated with more frequent cough, general pain/discomfort, and muscle weakness; as well as more severe breathlessness and dizziness. To the best of our knowledge, this is the first study

to state these findings, however, it does follow similar trends with regards to likelihood of contracting COVID-19³⁴ and the impact of socioeconomic factors on health outcomes after COVID-19 infection³⁵. As such, these findings stress a need to ensure that burden of cost for support whilst living with long-COVID should be distributed fairly to ensure minimal compounding of factors limiting society's most vulnerable members.

Smoking status

We found a significantly greater number of symptoms were reported by smokers vs non-smokers and smokers vs those who used to smoke, but this was the only significant association found between long-COVID symptoms and smoking status. This is the only study known to the authors to report smoking status effect on isolated symptoms, with exception to one study found smoking to have no effect on cough being reported as a primary symptom for hospitalisation ³⁶. Whilst studies found smoking to be associated with increased risk of reporting long-COVID symptoms ≥12 weeks after infection ^{37,38}, the evidence that smoking has significant effect on the impact of long-COVID itself has been lacking and requires further research to draw firmer conclusions.

Limitations

Limitations of this study focus on the self-report nature of the survey. This is discussed in detail in Part 2 [CITATION TO PART 2 MANUSCRIPT – EDITORIAL MANAGEMENT].

Conclusion

The results of this study show the most prevalent long-COVID symptoms in Scotland are PEM, fatigue and tiredness, cognitive impairment, breathlessness, headache, and sleep difficulties. Fatigue and tiredness, problems with ADL, general pain, mobility problems, and PEM were more frequently occurring, whilst sleep difficulties, problems with ADL, nausea and PEM were the most severely reported. Those living in a lower SIMD-rated postcode were likely to report a greater number of symptoms, severity, and frequency of some symptoms. Vaccine status, age, sex, and smoking status had limited or no effect on symptoms.

This information elucidates a picture of the challenges faced specifically for those living with long COVID in Scotland. Findings from this study may aid physicians, healthcare practitioners, and policy makers better understand the prevalence, frequency, and severity of symptoms of long-COVID. This is the first study to quantify individual symptoms in Scotland and, in conjunction with Part 2, demonstrates the large impact symptoms have on affected persons' ability to work and perform daily tasks. Given the heterogeneity of long-COVID, further depth of multidisciplinary research will be necessary to understand the pathophysiology of the disease and develop effective treatments and services to support those developing and continuing to live with long-COVID in the future.

References

- 1. Staffolani S, Iencinella V, Cimatti M, Tavio M. Long COVID-19 syndrome as a fourth phase of SARS-CoV-2 infection. *Infez Med*. 2022;30(1):22-29. doi:10.53854/liim-3001-3
- 2. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med*. 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- 3. Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review. *Front Med*. 2021;8:750378. doi:10.3389/fmed.2021.750378
- 4. Goertz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ OPEN RESEARCH*. 2020;6(4). doi:10.1183/23120541.00542-2020
- 5. Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. *PLoS One*. 2020;15(12):e0243882. doi:10.1371/journal.pone.0243882
- 6. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020;324(6):603-605. doi:10.1001/jama.2020.12603
- Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ*. 2022;377:e069676. doi:10.1136/bmj-2021-069676
- 8. Seaman R, Riffe T, Leyland AH, Popham F, van Raalte A. The increasing lifespan variation gradient by area-level deprivation: A decomposition analysis of Scotland 1981–2011. *Social Science & Medicine*. 2019;230:147-157. doi:10.1016/j.socscimed.2019.04.008
- Walsh D, McCartney G, Minton J, Parkinson J, Shipton D, Whyte B. Deaths from 'diseases of despair' in Britain: comparing suicide, alcohol-related and drug-related mortality for birth cohorts in Scotland, England and Wales, and selected cities. *J Epidemiol Community Health*. 2021;75(12):1195-1201. doi:10.1136/jech-2020-216220
- 10. Scarborough P, Morgan RD, Webster P, Rayner M. Differences in coronary heart disease, stroke and cancer mortality rates between England, Wales, Scotland and Northern Ireland: the role of diet and nutrition. *BMJ Open*. 2011;1(1):e000263. doi:10.1136/bmjopen-2011-000263
- Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. *Journal of Neurology, Neurosurgery & Psychiatry*. 2014;85(1):76-84. doi:10.1136/jnnp-2013-305450
- Office for National Statistics. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK - Released 30 March 2023. Office for National Statistics (ONS); 2023. Accessed March 31, 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddis eases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/lat est

- Office for National Statistics. Population Estimates for the UK, England, Wales, Scotland and Northern Ireland - Released 21 December 2022. Office for National Statistics (ONS); 2022. Accessed March 31, 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populatione stimates/bulletins/annualmidyearpopulationestimates/latest
- 14. Cotler J, Holtzman C, Dudun C, Jason LA. A Brief Questionnaire to Assess Post-Exertional Malaise. *Diagnostics (Basel)*. 2018;8(3):66. doi:10.3390/diagnostics8030066
- 15. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. *European Respiratory Journal*. 2020;56(5). doi:10.1183/13993003.03276-2020
- 16. Coronavirus (COVID-19): data for Scotland. Published June 8, 2022. Accessed March 28, 2023. http://www.gov.scot/publications/coronavirus-covid-19-data-for-scotland/
- 17. Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun*. 2022;101:93-135. doi:10.1016/j.bbi.2021.12.020
- Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):16144. doi:10.1038/s41598-021-95565-8
- 19. Munblit D, Nicholson T, Akrami A, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. *The Lancet Respiratory Medicine*. 2022;10(7):715-724. doi:10.1016/S2213-2600(22)00169-2
- 20. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Global Health*. 2021;6(9):e005427. doi:10.1136/bmjgh-2021-005427
- 21. Arienti C, Cordani C, Lazzarini SG, Del Furia MJ, Negrini S, Kiekens C. Fatigue, post-exertional malaise and orthostatic intolerance: a map of Cochrane evidence relevant to rehabilitation for people with post COVID-19 condition. *Eur J Phys Rehabil Med*. 2022;58(6):857-863. doi:10.23736/S1973-9087.22.07802-9
- 22. Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG. Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An Observational Study. *Phys Ther*. 2022;102(4):pzac005. doi:10.1093/ptj/pzac005
- 23. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. *J R Soc Med*. 2021;114(9):428-442. doi:10.1177/01410768211032850
- Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)—A systematic review and meta-analysis. *Journal of Medical Virology*. 2022;94(1):253-262. doi:10.1002/jmv.27309
- 25. Bisaccia G, Ricci F, Recce V, et al. Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic Dysfunction: What Do We Know? *JCDD*. 2021;8(11):156. doi:10.3390/jcdd8110156
- 26. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. *J R Soc Med*. 2021;114(9):428-442. doi:10.1177/01410768211032850

- Malik P, Patel K, Pinto C, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)—A systematic review and meta-analysis. *Journal of Medical Virology*. 2022;94(1):253-262. doi:10.1002/jmv.27309
- 28. Ziauddeen N, Gurdasani D, O'Hara ME, et al. Characteristics and impact of Long Covid: Findings from an online survey. *PLOS ONE*. 2022;17(3):e0264331. doi:10.1371/journal.pone.0264331
- 29. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. *Vaccines (Basel)*. 2022;10(5):652. doi:10.3390/vaccines10050652
- Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *eClinicalMedicine*. 2021;38. doi:10.1016/j.eclinm.2021.101019
- Wisnivesky JP, Govindarajulu U, Bagiella E, et al. Association of Vaccination with the Persistence of Post-COVID Symptoms. J GEN INTERN MED. 2022;37(7):1748-1753. doi:10.1007/s11606-022-07465-w
- 32. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med*. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- Sylvester SV, Rusu R, Chan B, Bellows M, O'Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. *Current Medical Research and Opinion*. 2022;38(8):1391-1399. doi:10.1080/03007995.2022.2081454
- 34. Prats-Uribe A, Paredes R, Prieto-Alhambra D. Ethnicity, comorbidity, socioeconomic status, and their associations with COVID-19 infection in England: a cohort analysis of UK Biobank data. Published online June 11, 2020:2020.05.06.20092676. doi:10.1101/2020.05.06.20092676
- 35. Little C, Alsen M, Barlow J, et al. The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort Study. *J Community Health*. 2021;46(4):794-802. doi:10.1007/s10900-020-00944-3
- 36. Fernández-de-Las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. *Lung*. 2021;199(3):249-253. doi:10.1007/s00408-021-00450-w
- Barthélémy H, Mougenot E, Duracinsky M, et al. Smoking increases the risk of post-acute COVID-19 syndrome: Results from a French community-based survey. *Tob Induc Dis.* 2022;20:59. doi:10.18332/tid/150295
- 38. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med*. 2022;28(8):1706-1714. doi:10.1038/s41591-022-01909-w